Nurse prescribing is the authority granted to registered nurses to assess, diagnose, and prescribe medications within a defined scope of practice, subject to regulatory approval and credentialing. It is linked to advanced practice roles and does not apply universally to all registered nurses.
The nurse takes full clinical responsibility for assessment and prescribing decision — no physician countersignature required. Requires advanced practice registration and specific competency assessment.
Nurse prescribes within an agreed Clinical Management Plan (CMP) in partnership with a medical prescriber. The nurse can prescribe any medicine in the CMP for a named patient. Common entry point for expanding prescribing roles in GCC.
GCC Key Point: Prescribing authority for nurses in the GCC is NOT universal. It is role-specific, credential-dependent, and varies significantly between countries and emirates. Always verify your scope with your facility and licensing body.
| Country / Authority | Regulatory Body | Prescribing Status for Nurses | Notes |
|---|---|---|---|
| UAE — Dubai | DHA (Dubai Health Authority) | APN Prescribing Authorised | Advanced Practice Nurses with DHA APN credential may prescribe within DHA formulary. Specific formulary list applies. |
| UAE — Abu Dhabi | DOH (Dept. of Health) | APN Prescribing Authorised | DOH Scope of Practice framework — APN prescribing under DOH formulary. Separate from DHA scope. |
| UAE — MOH | Ministry of Health & Prevention | Emerging / Limited | MOH regulates non-Emirate facilities. APN scope evolving — facility-level protocols often govern prescribing. |
| Saudi Arabia | SCFHS | Emerging — Limited | Advanced nursing roles expanding. SCFHS clinical nurse specialist/nurse practitioner tracks developing. Limited formulary prescribing emerging in select facilities. |
| Qatar | QCHP | Scope-Defined | QCHP scope of practice for specialist nurses and nurse practitioners. Prescribing linked to specialty certification and facility credentialing. |
| Oman | OMSB | Early Development | OMSB developing advanced nursing framework. Prescribing authority not yet formalised for most nursing roles. |
| Bahrain | NHRA | Early Development | National Health Regulatory Authority — advanced nursing role scope under review. Limited prescribing in pilot settings. |
| Kuwait | MOH Kuwait | Physician-Led Model | Predominantly physician prescribing model. Advanced nursing roles developing but formal prescribing authority limited. |
The Nurse Practitioner (NP) role is rapidly expanding across the GCC, particularly in UAE and Qatar. NPs function at an advanced level with:
Prescribing rights are earned through post-graduate qualification, competency assessment, and formal licensing body credentialing — not automatically granted on NP registration.
The UK Non-Medical Prescribing (NMP) model, adopted in part by GCC systems, distinguishes:
Nurse takes full responsibility. Can prescribe any medicine in the British National Formulary (BNF) within competence. Widely adopted as the aspiration for APN prescribing in GCC.
Prescribing within a physician-agreed Clinical Management Plan (CMP). Lower risk entry point — widely applicable in GCC hospital and community settings.
Limited to Community Practitioners Formulary (CPF) — dressings, some OTC preparations. Less relevant to GCC hospital context.
The duty to carry out a task. A nurse may be delegated the task of transcribing or administering a prescription — they are responsible for doing it correctly.
The legal and professional obligation to answer for your actions. The prescriber is always accountable for the prescription — this cannot be delegated.
Core Principle: If you sign the prescription, you are legally accountable for that clinical decision — regardless of who suggested the drug or what guidelines say. Never prescribe outside your competence.
DHA Formulary — approved drug list for Dubai-licensed facilities. Prescribers must use formulary drugs unless documented justification provided. Controlled drug prescribing requires specific DHA prescription forms.
Department of Health Abu Dhabi formulary — separate from DHA. Abu Dhabi Medication Safety Standards apply to all DOH-licensed facilities. Formulary review conducted regularly.
Saudi Food & Drug Authority — approves drugs for Saudi market. Facility formularies based on SFDA-approved medicines. Saudi MOH National Formulary provides guidance for public sector prescribing.
Qatar Council for Healthcare Practitioners oversees drug approval and prescribing standards. NCCCR and HMC formularies govern hospital prescribing.
MOH National Unified Registration System — governs drug registration across UAE. Prescribers in MOH facilities follow MOH formulary and controlled substance regulations.
Each GCC country maintains national drug registration and formulary systems. Practitioners working across borders must verify prescribing rules for each jurisdiction.
Controlled drugs (CDs) carry additional legal requirements beyond standard prescriptions in all GCC countries.
GCC Context: Strict CD regulations — non-compliance carries significant professional and criminal consequences. Always follow facility SOP and verify with pharmacy.
Prescribing a drug outside its licensed indications, dose, population, or route. Not illegal but requires:
Computerised Physician/Provider Order Entry systems — now mandatory or standard in most GCC tertiary hospitals (Dubai Health, Sidra, KFSH). Benefits:
CPOE Alert Fatigue: Over-alerting leads clinicians to override warnings. Good systems calibrate alert severity — critical alerts (anaphylaxis risk, contraindicated combination) must never be bypassed without documented reason.
Movement of drug from site of administration into bloodstream. Key factors: route of administration, drug formulation, gastric pH (achlorhydria in elderly, PPIs), gut motility, first-pass effect (oral drugs metabolised in liver before reaching systemic circulation — reduces bioavailability). Examples: GTN sublingual bypasses first-pass; morphine oral bioavailability ~30% due to high first-pass.
Spread of drug from blood to tissues. Volume of distribution (Vd) — large Vd means drug distributes widely into tissues (amiodarone, digoxin). Protein binding: only free drug is active — hypoalbuminaemia (liver disease, malnutrition) increases free fraction of highly protein-bound drugs (phenytoin, warfarin) → toxicity risk at normal doses.
Biotransformation — mainly liver (CYP450 system). Phase I (oxidation, reduction, hydrolysis) and Phase II (conjugation — glucuronidation). Prodrugs require metabolism to become active (codeine → morphine via CYP2D6). CYP450 inducers (rifampicin, carbamazepine, phenytoin) speed metabolism → reduced drug levels. CYP450 inhibitors (fluconazole, erythromycin, grapefruit) slow metabolism → increased drug levels and toxicity.
Primary route: renal (glomerular filtration, tubular secretion). Dose adjustment required when eGFR falls — renally-cleared drugs accumulate. Also biliary excretion (enterohepatic recirculation — digoxin, some antibiotics). Half-life (t½): time for plasma concentration to halve. Steady state reached at ~5 × t½. Renal impairment prolongs t½ of renally cleared drugs.
| Interactant | Effect on CYP450 | Clinical Result |
|---|---|---|
| Rifampicin | Strong inducer | Reduced warfarin, contraceptive pill levels — treatment failure |
| Fluconazole | Strong inhibitor | Increased warfarin → raised INR / bleeding risk |
| Erythromycin | CYP3A4 inhibitor | Increased simvastatin → rhabdomyolysis risk |
| Carbamazepine | Inducer | Reduced levels of many drugs — including itself (autoinduction) |
| Grapefruit juice | CYP3A4 inhibitor | Increased calcium-channel blocker and statin levels |
Drugs with a narrow therapeutic index or high potential for serious harm if used in error. All GCC accredited hospitals (JCI/CBAHI/ACHSI) require additional safety checks for high-alert medicines.
ISMP Rule: Concentrated potassium chloride (KCl) must NEVER be stored on general wards — only pharmacy-prepared IV bags. IV KCl bolus has caused cardiac arrest fatalities. This is a never event in GCC/JCI-accredited hospitals.
TDM is the measurement of drug plasma levels to ensure therapeutic concentrations while avoiding toxicity. Essential for drugs with narrow therapeutic windows.
| Drug | Therapeutic Range | Timing of Sample | Toxicity Signs |
|---|---|---|---|
| Vancomycin | Trough: 10–20 mg/L (AUC/MIC >400 preferred) | 30 min before 4th dose | Nephrotoxicity, ototoxicity, Red Man Syndrome |
| Gentamicin | Trough <1 mg/L (OD dosing) | Pre-dose trough; peak 1h post-dose | Nephrotoxicity (reversible), ototoxicity (irreversible) |
| Digoxin | 0.5–2.0 nanomol/L | Trough (6h post-dose minimum) | N&V, visual disturbance (yellow/green), bradycardia, arrhythmia |
| Phenytoin | 40–80 micromol/L (total) (correct for albumin) | Trough (pre-dose) | Nystagmus, ataxia, dysarthria, sedation |
| Lithium | 0.4–1.0 mmol/L (maintenance) | 12h post last dose | Tremor, polyuria, coarse tremor, convulsions, cardiac arrhythmia |
Use FDA pregnancy categories (A–X) or newer labelling (prescribing information includes human data). Avoid Category D/X unless benefit outweighs risk. Teratogenic risk highest in weeks 5–12 (organogenesis). Always use lowest effective dose. Examples to avoid: ACE inhibitors (2nd/3rd trimester — renal dysgenesis), valproate (neural tube defects), thalidomide (absolute contraindication), NSAIDs (3rd trimester — premature closure of ductus arteriosus).
STOPP (Screening Tool of Older Persons' Prescriptions) — drugs to STOP in elderly. START (Screening Tool to Alert doctors to Right Treatments) — drugs to consider starting.
Children are NOT small adults. Pharmacokinetics differ significantly — especially neonates (reduced protein binding, immature hepatic enzymes, reduced renal clearance). Calculate all doses by weight (mg/kg). Use BNFc (BNF for Children) or facility paediatric formulary. Maximum doses must always be checked. Consider formulation — oral liquids preferred; tablets not appropriate for all ages.
10-fold dose errors are the most common serious paediatric medication error — always double-check decimal point placement.
Paracetamol (regular 1g QDS) ± NSAID (ibuprofen, naproxen) ± adjuvant. Always prescribe regularly, not PRN, for persistent pain.
Add weak opioid: codeine (30–60mg QDS), tramadol (50–100mg QDS). Codeine is a prodrug — CYP2D6 poor metabolisers get no analgesia; ultra-rapid metabolisers risk toxicity.
Strong opioid: morphine (titrate from 5–10mg 4-hourly), oxycodone, hydromorphone, fentanyl patch (stable chronic pain). Always prescribe laxative with strong opioids — constipation is universal. Prescribe antiemetic for first 1–2 weeks.
| Drug | Dose equiv. to oral morphine 10mg |
|---|---|
| Codeine (oral) | 100mg |
| Tramadol (oral) | 100mg |
| Oxycodone (oral) | 5mg (ratio 2:1) |
| Morphine (IV/SC) | 5mg (oral:parenteral 2:1) |
| Fentanyl patch 12mcg/h | ~30mg oral morphine/24h |
GCC & Opioids: Strong opioids are Schedule II controlled drugs across GCC. Co-prescribe naloxone 400mcg IM/SC with take-home opioids where supported by local policy. In-hospital: always prescribe naloxone as reversal agent alongside opioid prescribing on drug chart.
| Risk / Weight | Dose | Frequency |
|---|---|---|
| Standard surgical / medical | 20–40mg SC | Once daily |
| Weight <50kg | 20mg SC | Once daily |
| Weight >100kg (obesity) | 40mg SC | BD — or use anti-Xa level guided dosing |
| eGFR <30 ml/min | Reduce dose — specialist guidance | Monitor anti-Xa levels |
Start 5–10mg day 1, check INR day 3–4. Use warfarin dosing nomogram or validated algorithm. Target INR 2–3 for AF, DVT/PE, mechanical heart valve (target may be higher). Numerous drug and food interactions (vitamin K foods reduce effect). Monthly INR monitoring when stable.
| Type | Onset | Peak | Duration |
|---|---|---|---|
| Rapid-acting (Aspart, Lispro) | 10–20 min | 1–3h | 3–5h |
| Short-acting (Soluble/Regular) | 30–60 min | 2–4h | 5–8h |
| Intermediate (NPH/Isophane) | 1–2h | 4–8h | 12–18h |
| Long-acting (Glargine, Detemir) | 1–2h | Peakless | 20–24h |
| Ultra-long (Degludec) | 1h | Peakless | >40h |
Basal-bolus (preferred for inpatients): long-acting once daily + rapid-acting with each meal ± correction doses. More physiological, better control, fewer hypoglycaemias than sliding scale.
Sliding scale (variable-rate IV insulin infusion): for sick/NBM/perioperative patients — titrate infusion rate to hourly CBG. NOT appropriate as sole long-term regimen.
NEVER abbreviate "units" as "U" or "IU" in handwritten prescriptions — "U" misread as "0" has caused 10-fold overdoses. Write "units" in full.
GCC Context: Antibiotic resistance rates are high across the region. Carbapenem-resistant organisms (CRO) are increasingly prevalent in GCC hospitals. Antimicrobial stewardship programmes (ASP) are now mandatory in JCI-accredited GCC institutions.
DHA and DOH maintain preferred formulary lists. In exams, know the preferred LABA/ICS combinations on GCC formularies (e.g. budesonide/formoterol, fluticasone/salmeterol). Generic prescribing is encouraged but brand substitution by pharmacists must be approved.
| Error Type | Definition | Example |
|---|---|---|
| Prescribing Error | Wrong drug, dose, indication, or contraindicated drug selected | Prescribing penicillin to documented penicillin-allergic patient |
| Transcription Error | Error copying prescription to drug chart or discharge summary | Metformin 500mg written as 5000mg when transcribed |
| Dispensing Error | Pharmacy error — wrong drug, strength, or label dispensed | Dispensing Glibenclamide instead of Glipizide |
| Administration Error | Nurse gives wrong drug, dose, route, time, or to wrong patient | IV morphine given IM; gentamicin given without checking trough |
| Monitoring Error | Failure to monitor drug effects or order appropriate tests | Starting warfarin without subsequent INR checks |
JCAHO / JCI standard: limit verbal orders to emergency situations only. Receiving nurse must write and read back order to prescriber. Written countersignature required within 24 hours. Never accept verbal orders for chemotherapy or high-alert medications.
Medication errors spike at care transitions. SBAR (Situation, Background, Assessment, Recommendation) structure for handover should explicitly include medication changes, pending labs, and monitoring requirements.
Patients on 5+ medications — exponential increase in drug interaction risk. Medication reconciliation at every care transition (admission, transfer, discharge) is a JCI/CBAHI standard in GCC hospitals.
LASA errors are among the most common and dangerous medication errors. GCC context: multiple brand names for same generic drug (market varies by country) compounds the risk.
| Drug A | Drug B | Risk | Mitigation |
|---|---|---|---|
| Celebrex (celecoxib — NSAID) | Celexa (citalopram — SSRI) | Wrong drug class dispensed | Tall Man Lettering: celeCOXib vs CITALopram |
| Amaryl (glimepiride — diabetic) | Reminyl (galantamine — dementia) | Hypoglycaemia in dementia patient | Prescribe by generic name always |
| Losartan | Lisinopril | Different class — same use, sound-alike | Verify full drug name and class before dispensing |
| Noradrenaline (IV vasopressor) | Adrenaline (IV cardiac/anaphylaxis) | 10× concentration error risk | Separate storage, labelled infusion pumps, independent double-check |
| Metformin | Metronidazole | Dispensing confusion in handwritten prescriptions | CPOE with drug name validation eliminates this |
| Hydralazine | Hydroxyzine | Antihypertensive vs antihistamine | Tall Man Lettering: hydrALAZINE vs hydrOXYzine |
GCC Generic Prescribing: Multiple brand names for the same generic exist across GCC markets (e.g. amoxicillin sold as Amoxil, Trimox, Wymox, Ospamox). Prescribing by generic name with dose and form reduces brand confusion errors and supports substitution by pharmacy.
Audit measures current prescribing practice against an agreed standard, then drives improvement. Common GCC hospital prescribing audits:
Near misses (errors caught before reaching patient) are MORE valuable for learning than incidents. UAE reporting systems:
Blame-Free Culture: All GCC accreditation standards (JCI, CBAHI, ACHSI) mandate a just culture — systems analysis, not individual blame, is the basis of medication incident investigation.
The process of comparing a patient's medication orders to all of the medications that the patient has been taking. Conducted at every care transition:
Polypharmacy Risk: Elderly GCC patients often take medications prescribed in multiple countries (home country + GCC) leading to duplications, contraindicated combinations, and missed diagnoses. Reconciliation is especially critical in this group.
| CKD Stage | eGFR (ml/min/1.73m²) | Description | Prescribing Implications |
|---|---|---|---|
| G1 | ≥90 | Normal or high | No dose adjustment for most drugs — check individual drug monographs |
| G2 | 60–89 | Mildly decreased | Monitor; avoid nephrotoxins; NSAIDs should be used with caution |
| G3a/3b | 30–59 | Mild–moderately decreased | Dose reduce: metformin (caution G3b, stop at <30), LMWH, many antibiotics |
| G4 | 15–29 | Severely decreased | Stop metformin, NSAIDs, many renally-cleared drugs. Specialist involvement recommended. |
| G5 | <15 | Kidney failure | Renal replacement therapy consideration. Consult nephrology. Most renally-cleared drugs require major adjustment or avoidance. |